TD Cowen maintains Ultragenyx Pharmaceutical at Buy, raises price target to $19 from $18
TD Cowen maintained its Buy rating on Ultragenyx Pharmaceutical and raised its price target to $19 from $18, implying a 14.3% upside from the Nov 3 close of $16.63. Recent analyst price targets for the company range from $16 to $22.
How this was made

The 30-second read
Why it matters
The upgrade signals confidence in the company's pipeline, potentially attracting new institutional interest.
Market read
A modest analyst upgrade for a micro‑cap biotech, likely to generate limited but positive short‑term price pressure.
What to watch
Upcoming clinical trial data or regulatory decisions could dominate price movement more than an analyst target change.
Background
Ultragenyx is a small‑cap biotech focused on rare diseases; analyst coverage is limited, making any rating change noteworthy.
Ticker impact
TD Cowen raised its price target on Ultragenyx Pharmaceutical to $19 from $18, indicating a fresh bullish analyst view.
likely upward pressure as the market digests the higher target
The new target adds ~5.6% upside potential; such upgrades typically generate short‑term buying interest.
Market effects
May marginally benefit other rare‑disease biotech peers as analysts reassess sector valuation.
Limited to US biotech space; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The target raise is modest and may already be priced in; investors could wait for more substantive catalysts.
Key entities
- AnalystTD Cowen
Equity research firm that raised the price target.
- CompanyUltragenyx Pharmaceutical
Biotech firm developing treatments for rare diseases.

